Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 08:30 AM ET – Building Permits (Mar)

✓ 08:30 AM ET – Housing Starts (Mar)

✓ 08:30 AM ET – Housing Starts (MoM) (Mar)

✓ 09:15 AM ET – Industrial Production (YoY) (Mar)

✓ 09:15 AM ET – Industrial Production (MoM) (Mar)

PREMARKET SNAPSHOT 📈

Stock Futures point to a lower open today, with the NASDAQ 100 leading the decline at over 1.6%.

SECTOR SNAPSHOT ✨

Sector Spotlight: Tech Tumble! Information Technology dives 1.99%, worst performer today.

Unusual Volume

📈 Trio Petroleum Corp. (TPET) jumped 22.09% to $0.63 on a whopping 179.91 million shares traded.

📈 Investors went wild, sending Soligenix Inc (SNGX) stock soaring 21.73% to $0.47 on a massive volume of 134.04 million shares after the company declared that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™.

📈 Abnormal activity shook SuperCom Ltd (SPCB), pushing it up 45.07% to $0.40 on a whopping 126.64 million shares traded.

📈 Hub Cyber Security Ltd (HUBC) stock recently closed 50.00% upper at $1.95 on substantial volume of 73.37 million shares.

📈 Longeveron Inc (LGVN) increase by 73.37% in a single trading session, with abnormally high trading volume of 56.7 million shares after announcing that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study results.

Premarket Movers

Dragonfly Energy Holdings Corp. (DFLI) experiences a substantial 56.88% surge in pre-market trading following the release fourth quarter 2023 and full year financial results.

ParaZero Technologies Ltd. (PRZO) sees a significant 19.81% increase, reaching a pre-market price of $1.33 after announcing its intention to enter the counter unmanned aircraft system (C-UAS or anti-drone) market, by developing dedicated solutions based on its advanced technology, as announced on February 27, 2024.

Novo Integrated Sciences, Inc. (NVOS) demonstrates a noteworthy 12.99% surge, with a pre-market price of $0.50 after reporting fiscal year 2024 second quarter financial results.

Important FDA 

Recently Announced

Supernus Pharmaceuticals, Inc. (SUPN) faced a pivotal moment on April 8, 2024, when the FDA decision regarding their drug SPN-830 for Parkinson’s disease was announced. Unfortunately, the outcome was a Complete Response Letter, indicating additional steps required for approval.

AbbVie (ABBV) received positive news on March 22, 2024, regarding their drug ELAHERE, intended for platinum-resistant Ovarian Cancer. The FDA decision to convert its accelerated approval to full approval for certain patient groups marks a significant milestone in the treatment landscape for this challenging condition.

Bristol-Myers Squibb Co. (BMY) achieved a notable milestone on March 7, 2024, with the FDA approval of Opdivo in combination with cisplatin-based chemotherapy for urothelial carcinoma. This approval provides a new frontline treatment option for adult patients with unresectable or metastatic disease, potentially improving outcomes and quality of life.

Upcoming Announcements

In April 2024, the FDA is poised to make three pivotal decisions that could potentially reshape treatment strategies for various patient populations within the biopharmaceutical industry.

ImmunityBio, Inc. (IBRX) anxiously anticipates a crucial FDA decision scheduled for April 23rd regarding the use of N-803 plus BCG for high-risk non-muscle-invasive bladder cancer. This decision has the potential to revolutionize the management of bladder cancer.

Aquestive Therapeutics Inc. (AQST) eagerly awaits the FDA's imminent ruling on April 28th regarding Libervant (diazepam) Buccal Film, aimed at addressing seizure clusters in children aged two to five. This innovative treatment approach holds significant promise for transforming the care of pediatric epilepsy.

XOMA Corporation (XOMA) is prepared for a significant FDA decision on April 30th regarding tovorafenib, intended for the treatment of relapsed or progressive pediatric low-grade glioma (pLGG). This decision carries profound implications for pediatric oncology, offering hope to children facing this challenging diagnosis.

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.